Wijnegem, Belgium, July 26th 2016: Novosanis announced today their collaboration with ImevaX, a biopharmaceutical company based in Munich, Germany. ImevaX developed a vaccine against the pathogen Helicobacter pylori (H. pylori) that can cause chronic stomach sores and ulcers potentially leading to gastric cancer. Novosanis will supply the VAX-ID™ device that allows for a standardized and accurate injection of the vaccine for their clinical trials. 

The VAX-ID™ device by Novosanis

The VAX-ID™ device by Novosanis

ImevaX develops highly specific vaccines against pathogens that cause chronic infectious diseases. H. pylori leads to one of the most common bacterial infections worldwide. Considering that the efficacy of existing antibiotics decreases, there is a high unmet medical need for a H. pylori vaccine.

Novosanis’ part in the clinical trials is related to the administration of the vaccines using their medical device VAX-ID™. This delivery system is suited for injection into the dermal layer of the skin. One of the advantages of intradermal injection is the improved immune response evoking a quicker and more responsive reaction from the patient. The advantage of VAX-ID™ is the decreased loss of dose due to the accuracy of the injection and ease of use that de-skills its use even more.

Vanessa Vankerckhoven, CEO Novosanis stated: “Due to the high incidence of H. pylori infections, we’re glad to be part of a possible solution by ImevaX. Our VAX-ID™ injection device will bring some significant benefits to the clinical trial and finally to possible vaccination campaigns, like its accuracy, ease-of-use and especially its dose-sparing potential.”

“More than 50% of the world population carries the H. pylori bacteria which could lead to gastric cancer, so it’s necessary to reach as many people as possible to treat or even prevent these infections.” says Dr. Marie Roskrow, CEO at ImevaX.

About Novosanis
Novosanis is an innovative developer and producer of medical devices adding value to the accuracy of diagnostics tests, vaccination based actions and the overall patient’s comfort.
We are a medical device company active in the field of infectious diseases and oncology in the areas of prevention, detection and treatment.
Novosanis prospers in user-friendly and smart medical devices meeting all regulatory and quality requirements, solutions that can improve the accuracy of the diagnostic test while making the handling easier, more consistent and more comfortable for the person.
Currently we have two device platforms in portfolio: VAX-ID™, suited for accurate intradermal injections and Colli-Pee™, suited for standardized collection of first void urine. Colli-Pee™ is in commercial stage and is CE marked. For more information, please visit: www.novosanis.com

About ImevaX
ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines. The company’s lead candidate IMX 101 is a vaccine against Helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Founder Markus Gerhard and his team discovered that the colonization ability (and hence, the infectiousness) of H. pylori depends on a secreted bacterial factor that down-regulates the host immune system. Many other highly infectious pathogens have evolved similar immune evasion mechanisms, which are the focus of the ImevaX screening program. For more information, please visit: www.imevax.com

About VAX-ID
VAX-ID™ (patent pending) is an easy to use pre-filled device suited for accurate intradermal injection, i.e. injection in the dermis, the skin layer underneath the epidermis or upper layer of the skin. Intradermal injection allows for an improved immune response. VAX-ID™ is safe to use as needle-stick injuries are avoided through a unique activation and deactivation mechanism. VAX-ID™ can be used for both prophylactic and therapeutic intradermal vaccination as well as for biologicals. VAX-ID™ is a device platform that is currently in development stage. The platform will allow injection of different volumes, use of different needle thicknesses and length depending on the application. For more information, please visit: www.novosanis.com/devices/vax-id

For more information, please contact:
Julie Post, Communication Manager Novosanis
+32 3 485 50 16
press@novosanis.com